Expression of HER2/neu in primary and metastatic breast cancer

Polish Journal of Pathology

Volumn 52, Issue 1-2, 2001, Pages 21-26

  Tuziak, T ^a   Olszewski, W P ^a   Olszewski, W ^a   Pienkowski T ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 0034941140     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Breast carcinoma: Evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers
2. Amplification of c-erbB-2 and aggressive human breast tumor
3. Overexpression of Her-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
4. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
5. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
6. c-myc amplification is a better prognostic factor than HER-2/neu amplification in primary breast cancer
7. Amplification and protein over-expression of the neu/HER-2/c-erbB2 protooncogene in human breast carcinomas. Relationship to loose of gene sequences on chromosome 17, family history and prognosis
8. Proto-oncogene abnormalities in human breast cancer: Correlation with anatomic features and clinical course of disease
9. A 50-kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of neu/HER-2 in human SK-BR-3 mammary cancer cells
10. Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast
11. erbB2 protein is localized on cell organelles involved in cell motility
12. Neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast
13. Functional assay for HER-2/neu demonstrates active signaling in a minority of HER-2/neu-overexpressing invasive human breast tumors
14. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor
15. C-erbB2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
16. Prognostic importance of c-erbB-2 expression in breast cancer
17. C-erbB-2 expression in benign and malignant breast disease
18. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study
19. Amplification of c-erbB2 oncogene and prognosis of breast adenocarcinoma
20. Maintenance of DNA content and c-erbB-2 alterations in intraductal and invasive phases of mammary cancer
21. Increased erbB-2 gene copies and expression in multiple stages of breast cancer
22. Elevated c-erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer
23. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erbB-2 overexpression and vascular invasion
24. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
25. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of erbB2 as a critical component in mediating heregulin responsiveness
26. Prognostic value of erbB2 and myc amplification in breast cancer imprints
27. c-erbB2 oncoprotein expression in primary and advanced breast cancer
28. Quantitative immunohistochemistry using the CAS 200/468 image analysis system in invasive breast carcinoma: A reproducibility study
29. Human breast cancer: Identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression
30. Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma
31. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues
32. Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
33. Pathologic findings from the National Surgical Adjuvant Breast Project: Prognostic significance of erbB2 protein overexpression in primary breast cancer
34. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
35. Monoclonal antibody to Her-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cell overexpressing this oncogene
36. Neoplasia
37. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
38. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities
39. HER-2/neu oncogene protein and prognosis in breast cancer
40. Prognostic significance of cathepsin D expression in node-positive breast carcinoma: An immunohistochemical study
41. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer
42. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up
43. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: Hst-1/int-2 and c-erbB2/ear-1
44. Immunohistochemical study on overexpression of c-erbB2 protein in human breast cancer: Its correlation with gene amplification and long-term survival of patients
45. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
46. Alterations to either c-erbB2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
47. An evaluation for immunoreactivity for c-erbB2 protein as a marker of poor short-term prognosis in breast cancer
48. Expression of c-erbB2 oncoprotein: A prognostic indicator in human breast cancer
49. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
50. Proto-oncogene abnormalities in human breast cancer: C-erbB-2 amplification does not correlate with recurrence of disease
51. Association of multiple copies of the c-erbB2 oncogene with spread of breast cancer